Third Rock Continues To Attract Investors, Closes $516M Fund
This article was originally published in The Pink Sheet Daily
The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.
You may also be interested in...
The 27th annual Beyond Borders report shows continued constraints to funding for biotechs, as they cut R&D and deal with a changing development landscape, but VC funding remains resilient.
The Massachusetts start-up has plans to create five new companies that will focus on rare disease work through an innovative business model that will de-risk the assets before spinning them out into separate biotech companies.
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.